# Beijing Saiqiao Biological Technology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/beijing-saiqiao-biological-technology

- Industry: Medical Devices & Equipment
- Headquarters: Shenzhen, China
- Website: www.cellbri.com
- Total disclosed funding: $28M
- Latest round: Series B (Mar 18, 2025)
- Investors on record: 10

## About

Established in 2020 and based in Shenzhen, China, Beijing Saiqiao Biological Technology operates as a biotechnology service provider that provides CGT solutions. It has set up subsidiaries in Hangzhou, Beijing, and Shanghai, has acquired 7 invention patents. The core team are from Tsinghua University and Deutsche Akademie der Technikwissenschaften. The co-founder and CTO, Xiaoliang Guo has more than 10 years of experience in the field of automated cell processing and analysis technology and biological precision instruments. In January 2021, the company launched fully enclosed automated cell production equipment, Gentle Harv 2000. In March 2025, it closed series B+ funding from new investors Fosun Health Capital and Changzhou Gaoxintou Venture.  

Beijing Saiqiao Biological Technology focuses on providing CGT intelligent manufacturing solutions. The company's products include magnetic bead activated sorters, liquid transfer machines, cell expansion systems, preparation dispensing, takeover machines and other equipment, as well as matching GMP disposable containment consumables. It has a self developed fully enclosed automated cell production equipment, Gentle Harv 2000 that use to the commercial production of cell pharmaceuticals.

The company generates revenue by offering CGT solutions and related digital process equipment.

The company will use the series B+ funding to further promote its technology research and development and market expansion.

## Funding rounds

- Series B, Mar 18, 2025 — Changzhou Gaoxintou Venture, Fosun Health Capital
- Series B, Jun 14, 2024, $28M — 3E Bioventures Capital, Tengye Ventures, Changkejin  Investment, Hongsheng Junhao Investment, Tsinghua Innovation Ventures, Shenzhen Investment Control Capital
- Series A, Oct 15, 2021 — Delian Capital, MPC
- Angel, Apr 15, 2020 — Tsinghua Innovation Ventures

## Investors

- Tsinghua Innovation Ventures (https://capitalatlas.ai/funds/tsinghua-innovation-ventures) — Angel, Series B
- Delian Capital (https://capitalatlas.ai/funds/delian-capital) — Series A
- MPC — Series A
- 3E Bioventures Capital (https://capitalatlas.ai/funds/3e-bioventures-capital) — Series B
- Tengye Ventures (https://capitalatlas.ai/funds/tengye-ventures) — Series B
- Changkejin  Investment — Series B
- Hongsheng Junhao Investment (https://capitalatlas.ai/funds/hongsheng-junhao-investment) — Series B
- Shenzhen Investment Control Capital (https://capitalatlas.ai/funds/shenzhen-investment-control-capital) — Series B
- Changzhou Gaoxintou Venture (https://capitalatlas.ai/funds/changzhou-gaoxintou-venture) — Series B
- Fosun Health Capital (https://capitalatlas.ai/funds/fosun-health-capital) — Series B